Comparative Pharmacology
Head-to-head clinical analysis: PROTONIX versus PROTONIX IV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROTONIX versus PROTONIX IV.
PROTONIX vs PROTONIX IV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor that inhibits the H+/K+-ATPase enzyme system at the secretory surface of gastric parietal cells, blocking the final step of gastric acid secretion.
Pantoprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase enzyme system at the secretory surface of gastric parietal cells.
40 mg orally once daily; alternatively, 40 mg IV once daily for 7-10 days.
40 mg intravenously once daily for 7-10 days; for pathological hypersecretory conditions, initial dose 80 mg IV every 12 hours, titrate per acid output.
None Documented
None Documented
Terminal elimination half-life is about 1–2 hours in healthy individuals; in CYP2C19 poor metabolizers or hepatic impairment, half-life may increase up to 3–6 hours, but clinical impact is minimal due to irreversible binding to H+/K+-ATPase.
1-2 hours in healthy subjects; prolonged to 3.5-8 hours in hepatic impairment.
Approximately 80% of a dose is excreted as metabolites in urine, with the remainder (≈20%) in feces via biliary elimination.
Primarily hepatic metabolism; 71-82% of dose excreted in urine as metabolites, 18-20% in feces.
Category C
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor